Iloprost infusion by a new device as a portable syringe pump: safety, tolerability and agreement

Submitted: 7 December 2012
Accepted: 7 December 2012
Published: 10 December 2012
Abstract Views: 1102
PDF: 1205
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Iloprost, prostacyclin (PGI2) analogue, effective in treatment of peripheral arterial disease, secondary Raynaud's phenomenon (RP) to connective tissue disease (CTD), vasculitis, pulmonary hypertension, is usually infused through peristaltic pump, or recently through a flow regulator.

Materials and methods
We tested a new portable syringe pump (Pompa Infonde®, Italfarmaco S.p.A., Cinisello Balsamo, Milano) on 120 patients affected by RP to CTD and cryoglobulinaemia, in iloprost therapy with a flow regulator.

Iloprost infused through portable syringe pump is better tolerated, better appreciated by the patients and nurses and no difference was observed on therapeutic effects, with a lower incidence of side effects statistically significant. Only 3 patients were unable to tolerate the device (2 for changes in pressure and 1 for fear) and shifted to traditional method of iloprost infusion.

Iloprost infusion through the portable syringe Pompa Infonde® appears to be safe, better tolerated, more acceptable and equally effective compared to infusion through a flow regulator.



PlumX Metrics


Download data is not yet available.


How to Cite

Faggioli, P., Sciascera, A., Giani, L., & Mazzone, A. (2012). Iloprost infusion by a new device as a portable syringe pump: safety, tolerability and agreement. Italian Journal of Medicine, 6(4), 311–314.